Atossa Therapeutics price to sales ratio ATOS

Market value divided by revenue over the last twelve months, since 2013.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 2.5×; Apr 2016
Peer median: 0.4×

Atossa Therapeutics' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Apr 2016, at 2.5×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2016	2.5×	1.1×	3.0×
2015	1.7×	1.7×	79.7×
2014	153×	45.6×	181×
2013	63.0×	38.9×	125×

Against its peers

Companies in Drug Manufacturers - General nearest Atossa Therapeutics' size, closest first, today.

Company	Price to sales ratio
ATOSAtossa Therapeutics	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
NATRNatures Sunshine Products	0.4×
Peer median	0.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Atossa Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.